Lv42
490 积分 2024-09-18 加入
Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
5小时前
求助中
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
5小时前
已完结
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
9小时前
已完结
High-Risk MCL: Recognition and Treatment
7天前
已完结
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
7天前
已完结
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
7天前
已完结
Treatment of Relapsed/Refractory MCL
7天前
已完结
Frontline Treatment of Mantle Cell Lymphoma
10天前
已完结
Treatment of Relapsed/Refractory MCL
10天前
已完结
Mantle-Cell Lymphoma
13天前
已完结
皖公网安备34019202002308
